Akatsu T, Takahashi N, Udagawa N, Sato K, Nagata N, Moseley J M, Martin T J, Suda T
Department of Biochemistry, School of Dentistry, Showa University, Shinagawa-ku, Japan.
Endocrinology. 1989 Jul;125(1):20-7. doi: 10.1210/endo-125-1-20.
Induction of osteoclast-like multinucleated cells (MNCs) by various fragments of PTH-related protein (PTHrP) was examined in mouse marrow cultures. Osteoclast-like MNCs were defined as tartrate-resistant acid phosphatase (TRACP)-positive MNCs with calcitonin receptors. In all experimental protocols examined, PTHrP-(1-34) induced TRACP-positive MNCs at almost the same rate as PTH-(1-34). PTHrP-(1-29) was less potent than PTHrP-(1-34). PTHrP-(1-25) and PTHrP-(1-14) had no effect. PTHrP-(1-34) was more potent than PTH-(1-34) in increasing the accumulation of cAMP, but the former appeared to lose its activity more rapidly than the latter. Isobutylmethylxanthine increased the effect of PTHrP-(1-34) and PTH-(1-34) in inducing TRACP-positive MNCs. Furthermore, the calcium ionophore A23187 significantly increased the formation of TRACP-positive MNCs. The effect of PTH-(1-34) and PTHrP-(1-34) in inducing TRACP-positive MNCs was potentiated by adding A23187 but suppressed by adding verapamil simultaneously. The inhibition by verapamil was overcome by adding A23187. [Nle8,18,Tyr34]PTH-(3-34)amide inhibited the effect of not only PTH-(1-34) but also PTHrP-(1-34) in inducing both the accumulation of cAMP and the TRACP-positive MNC formation. These results show that PTHrP is a potent stimulator of osteoclast-like MNC formation to almost the same extent as PTH. It increases the number of osteoclast-like MNCs by a mechanism involving cAMP and calcium ions, and is most likely mediated through the same receptor. The controversial results of the bone-resorbing activity of PTH and PTHrP reported so far may be explained by the differences in the relative potencies of the respective hormones in increasing the intracellular cAMP and calcium ions and by the shorter half-life of PTHrP in culture medium.
在小鼠骨髓培养物中检测了甲状旁腺激素相关蛋白(PTHrP)的各种片段诱导破骨细胞样多核细胞(MNCs)的情况。破骨细胞样MNCs被定义为具有降钙素受体的抗酒石酸酸性磷酸酶(TRACP)阳性MNCs。在所有检测的实验方案中,PTHrP-(1-34)诱导TRACP阳性MNCs的速率几乎与PTH-(1-34)相同。PTHrP-(1-29)的效力低于PTHrP-(1-34)。PTHrP-(1-25)和PTHrP-(1-14)没有作用。PTHrP-(1-34)在增加cAMP积累方面比PTH-(1-34)更有效,但前者似乎比后者更快失去活性。异丁基甲基黄嘌呤增加了PTHrP-(1-34)和PTH-(1-34)诱导TRACP阳性MNCs的作用。此外,钙离子载体A23187显著增加了TRACP阳性MNCs的形成。添加A23187可增强PTH-(1-34)和PTHrP-(1-34)诱导TRACP阳性MNCs的作用,但同时添加维拉帕米则会抑制该作用。添加A23187可克服维拉帕米的抑制作用。[Nle8,18,Tyr34]PTH-(3-34)酰胺不仅抑制PTH-(1-34)诱导cAMP积累和TRACP阳性MNC形成的作用,也抑制PTHrP-(1-34)的该作用。这些结果表明,PTHrP在刺激破骨细胞样MNC形成方面的效力与PTH几乎相同。它通过涉及cAMP和钙离子的机制增加破骨细胞样MNC的数量,并且很可能是通过相同的受体介导的。迄今为止报道的关于PTH和PTHrP骨吸收活性的有争议结果,可能是由于各自激素在增加细胞内cAMP和钙离子方面的相对效力不同,以及PTHrP在培养基中的半衰期较短所致。